2022 - Research.com Best Scientist Award
2012 - Warren Alpert Foundation Prize For the discovery, preclinical and clinical development of bortezomib to FDA approval and front line therapy for the treatment of patients with multiple myeloma.
2010 - Member of the National Academy of Medicine (NAM)
Member of the Association of American Physicians
His primary scientific interests are in Multiple myeloma, Cancer research, Bortezomib, Internal medicine and Bone marrow. His work deals with themes such as Pharmacology and Dexamethasone, which intersect with Multiple myeloma. Kenneth C. Anderson interconnects Cell culture, Apoptosis, Protein kinase B, Signal transduction and Cell growth in the investigation of issues within Cancer research.
His Bortezomib research focuses on subjects like Proteasome inhibitor, which are linked to Cancer cell. The Internal medicine study combines topics in areas such as Gastroenterology, Endocrinology, Surgery and Oncology. His study in Bone marrow is interdisciplinary in nature, drawing from both Molecular biology, Stromal cell, Immune system and Peripheral blood mononuclear cell.
Kenneth C. Anderson mainly focuses on Multiple myeloma, Cancer research, Internal medicine, Bortezomib and Immunology. The concepts of his Multiple myeloma study are interwoven with issues in Bone marrow, Dexamethasone and Pharmacology. His studies deal with areas such as Monoclonal antibody, Angiogenesis, Cytokine and In vivo as well as Bone marrow.
Within one scientific family, Kenneth C. Anderson focuses on topics pertaining to Apoptosis under Cancer research, and may sometimes address concerns connected to Cytotoxicity. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Surgery and Oncology. His work deals with themes such as Proteasome inhibitor, Proteasome and Refractory, which intersect with Bortezomib.
His primary areas of investigation include Multiple myeloma, Cancer research, Internal medicine, Oncology and Bortezomib. The Multiple myeloma study combines topics in areas such as Bone marrow and Transplantation. His research integrates issues of Cell culture, Cell growth, Antigen and Immunotherapy in his study of Cancer research.
In most of his Internal medicine studies, his work intersects topics such as Gastroenterology. Kenneth C. Anderson has included themes like Clinical trial, Survival rate, Confidence interval, Meta-analysis and Minimal residual disease in his Oncology study. His research in Bortezomib intersects with topics in Proteasome inhibitor, Proteasome and Pharmacology.
Kenneth C. Anderson spends much of his time researching Multiple myeloma, Cancer research, Internal medicine, Lenalidomide and Oncology. Kenneth C. Anderson combines subjects such as Survival rate and Bone marrow with his study of Multiple myeloma. His Cancer research study focuses on Stromal cell in particular.
The Internal medicine study which covers Gastroenterology that intersects with Antibody-drug conjugate and Indatuximab ravtansine. His Lenalidomide study combines topics in areas such as Surgery, Transplantation, Progressive disease and Thalidomide. The various areas that Kenneth C. Anderson examines in his Oncology study include Meta-analysis and Proportional hazards model.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal.
The New England Journal of Medicine (2003)
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore;Ghayas C. Issa;Madeleine E. Lemieux;Peter B. Rahl.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Teru Hideshima;Paul Richardson;Dharminder Chauhan;Vito J. Palombella.
Cancer Research (2001)
LOFAR: The LOw-Frequency ARray
M. P. van Haarlem;M. W. Wise;A. W. Gunst;G. Heald.
arXiv: Instrumentation and Methods for Astrophysics (2013)
LOFAR: The LOw-Frequency ARray
M. P. van Haarlem;M. W. Wise;M. W. Wise;A. W. Gunst;George Heald.
Astronomy and Astrophysics (2013)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima;Dharminder Chauhan;Dharminder Chauhan;Yoshihito Shima;Yoshihito Shima;Noopur Raje;Noopur Raje.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: